CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+6.21%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$907M
AUM Growth
+$907M
(+28%)
Cap. Flow
+$198M
Cap. Flow
% of AUM
21.86%
Top 10 Holdings %
Top 10 Hldgs %
37.32%
Holding
435
New
22
Increased
337
Reduced
40
Closed
7
Top Buys
| 1 |
Apple
AAPL
|
$25.8M |
| 2 |
Microsoft
MSFT
|
$10.9M |
| 3 |
Amgen
AMGN
|
$7.28M |
| 4 |
NVIDIA
NVDA
|
$6.87M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$6.77M |
Top Sells
| 1 |
Micron Technology
MU
|
$6.44M |
| 2 |
ServiceNow
NOW
|
$5.1M |
| 3 |
Salesforce
CRM
|
$5M |
| 4 |
CrowdStrike
CRWD
|
$4.33M |
| 5 |
Qualcomm
QCOM
|
$3.38M |
Sector Composition
| 1 | Technology | 37.6% |
| 2 | Healthcare | 28.11% |
| 3 | Consumer Discretionary | 12.57% |
| 4 | Communication Services | 9.53% |
| 5 | Consumer Staples | 3.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Arbutus Biopharma
ABUS
$753M
| $140K | 0.02% |
36,309
+14,138
| +64% | +$54.4K |
|
|
AUTL
327
Autolus Therapeutics
AUTL
$383M
| $139K | 0.02% |
38,393
+14,959
| +64% | +$54.3K |
|
328
Oric Pharmaceuticals
ORIC
$1.03B
| $139K | 0.02% |
13,568
+5,646
| +71% | +$57.9K |
|
|
HSAI
329
Hesai Group
HSAI
$3.42B
| $138K | 0.02% |
29,500
+9,500
| +48% | +$44.6K |
|
330
Consumer Discretionary Select Sector SPDR Fund
XLY
$23.2B
| $135K | 0.01% |
+672
| New | +$135K |
|
331
Savara
SVRA
$591M
| $134K | 0.01% |
31,658
+15,423
| +95% | +$65.4K |
|
332
Pacira BioSciences
PCRX
$1.22B
| $134K | 0.01% |
8,872
+3,404
| +62% | +$51.2K |
|
333
Olema Pharmaceuticals
OLMA
$432M
| $132K | 0.01% |
11,014
+4,442
| +68% | +$53K |
|
334
Pliant Therapeutics
PLRX
$105M
| $131K | 0.01% |
11,694
+4,607
| +65% | +$51.6K |
|
335
ChargePoint
CHPT
$252M
| $130K | 0.01% |
95,000
| – | – |
|
336
CureVac
CVAC
$1.21B
| $127K | 0.01% |
43,143
+16,792
| +64% | +$49.4K |
|
337
Tourmaline Bio
TRML
$645M
| $127K | 0.01% |
4,932
+1,920
| +64% | +$49.4K |
|
338
SPDR S&P 500 ETF Trust
SPY
$656B
| $127K | 0.01% |
+220
| New | +$127K |
|
339
Ironwood Pharmaceuticals
IRWD
$201M
| $127K | 0.01% |
30,723
+12,047
| +65% | +$49.6K |
|
340
Humacyte
HUMA
$231M
| $125K | 0.01% |
22,955
+8,965
| +64% | +$48.8K |
|
341
Scholar Rock
SRRK
$3.3B
| $123K | 0.01% |
15,393
+6,023
| +64% | +$48.2K |
|
342
Arcturus Therapeutics
ARCT
$467M
| $121K | 0.01% |
5,201
+2,038
| +64% | +$47.3K |
|
343
Schrodinger
SDGR
$1.42B
| $119K | 0.01% |
6,410
| – | – |
|
344
TJX Companies
TJX
$155B
| $118K | 0.01% |
1,000
| – | – |
|
345
HUTCHMED
HCM
$2.62B
| $117K | 0.01% |
5,966
+2,321
| +64% | +$45.3K |
|
346
Mineralys Therapeutics
MLYS
$1.94B
| $116K | 0.01% |
9,564
+3,732
| +64% | +$45.2K |
|
347
Terns Pharmaceuticals
TERN
$651M
| $113K | 0.01% |
13,535
+5,935
| +78% | +$49.5K |
|
348
Y-mAbs Therapeutics
YMAB
$390M
| $113K | 0.01% |
8,572
+3,416
| +66% | +$44.9K |
|
349
Allogene Therapeutics
ALLO
$249M
| $113K | 0.01% |
40,219
+15,690
| +64% | +$43.9K |
|
350
Galapagos
GLPG
$2.06B
| $112K | 0.01% |
3,899
+1,510
| +63% | +$43.5K |
|